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Over the past dozen years, the majority of clinical gene therapy trials for inherited genetic diseases and cancer therapy have been
performed using murine onco-retrovirus as the gene delivery vector. The earliest systems used were relatively inefficient in both the rates of
transduction and expression of the transgene. Formidable obstacles inherent in the cell biology and/or the immunology of the target cell
systems limited the efficacy of gene therapy for many target diseases. Development of novel retrovirus gene transfer systems that are in
progress have begun to overcome these obstacles. Evidence of this progress is the recent successful functional correction of the immune T
and B lymphocyte deficiency in patients with X-linked severe combined immunodeficiency (X-SCID) and adenosine deaminase (ADA)-
deficient SCID following onco-retrovirus vector ex vivo transduction of autologous marrow stem cells [Science 296 (2002) 2410; Science
288 (2000) 669; N. Engl. J. Med. 346 (2002) 1185]. These achievements of prolonged clinical benefit from gene therapy were tempered by
the finding of insertional mutageneses in two of the treated X-SCID patients [N. Engl. J. Med. 348 (2003) 255].Published by Elsevier Science B.V.Keywords: Onco-retrovirus; Gene therapy; Lentivirus1. Introduction
The first series of clinical trials of gene transfer with
retrovirus vectors demonstrated that the achievement of high
levels of prolonged gene expression seen inmice could not be
achieved in humans [5,6]. Concern was raised that achieve-
ments in the clinic would require extensive efforts to enhance
the basic science of gene therapy (Report and Recommenda-
tions of the Panel to Assess the NIH Investment in Research
on Gene Therapy, December 7, 1995, co-chaired by Stuart H.
Orkin, M.D., and Arno G. Motulsky, M.D., online site: http://
www4.od.nih.gov/oba/rac/documents1.htm). Despite these
initial disappointments, it remained clear that for many
patients with inherited and acquired diseases that could not
be treated with drugs, therapeutic protein therapies or allo-
geneic transplantation, gene therapy might be the sole option
for cure. However, the biological obstacles that require
solution include low rates of transduction, low protein0167-4889/03/$ - see front matter. Published by Elsevier Science B.V.
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tor, risk from insertional mutagenesis, and in the case of
hematopoietic stem cells (HSC) the numerical disadvantage
of the engrafting transduced stem cells relative to the resident
stem cells. We will review the current progress toward
solving these problems as it relates to retrovirus vectors.2. Retrovirus biology
Retroviruses are named for their ability to transcribe
RNA into DNA. When classified by nucleotide sequence
relationship, retroviruses are comprised of seven different
groups: avian-leukosis-sarcoma viral group (e.g. Rous sar-
coma virus), mammalian C-type viruses (e.g. Moloney
murine leukemia virus (MLV)), B-type viral group, D-type
viral group, bovine leukemia virus–human T cell leukemia
virus (BLV–HTLV), spumaviruses (e.g. foamy virus) and
lentiviruses (e.g. HIV). The first five viral groups have
oncogenic potential and are referred to as onco-retroviruses.
Hence, it would seem possible to simplify consideration of
these as three major groupings as onco-retroviruses, spu-
maviruses and lentiviruses. However, this simplification is
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retrovirus grouping together with the spumaviruses and
lentiviruses are ‘complex’ viruses encoding additional reg-
ulatory elements relative to the ‘simple’ retroviruses [7].
Because such regulatory elements may be responsible for
some of the pathogenic potential, for purposes of vector
engineering, the ‘complex’ retroviruses present some addi-
tional considerations relating to the elimination of regula-
tory elements from the transfer vector. All of these viruses
need host cells for their propagation as indicated in the
simplified life cycle outline below:
 Receptor binding.
 Entry and internalization.
 Reverse transcription.
 Assembly of pre-integration complex.
 Nuclear transport—during mitosis only (onco-retrovirus)
or during mitosis and interphase (lentivirus, spumavirus).
 Integration of provirus.
 Transcription from integrated virus—full length and
spliced versions of mRNA export.
 Translation primarily from spliced mRNA.
 Virion assembly—requires the packaging signal w
adjacent to the 5Vlong terminal repeat (LTR) and allows
encapsidation of the unspliced RNA only.
 Exit from the cell—requires budding, at which time the
virus acquires the envelope that gives the virus its species
and tissue tropism.
All retroviruses contain three coding domains: gag, pol
and env. The gag domain yields the matrix-, capsid- and
nucleoproteins; the pol domain yields the viral protease
(pro) together with the reverse transcriptase (RT) and
integrase, while the env domain encodes the envelope
glycoprotein. The infection and integration events of the
life cycle of the ‘simple’ retroviruses will be outlined below.
While the general scheme also applies to the complex
retroviruses, the accessory genes encoding regulatory ele-
ments modify those events.
2.1. Simple onco-retroviruses
Retroviruses have two identical single-stranded RNA
molecules in the nucleocapsid. The two single-stranded
RNA molecules have a 5Vcap and 3VpolyA tail and form
a weak dimer linkage structure at several sites along the
strands. The molecular structure of each single-stranded
‘simple’ retroviral RNA molecule is the following:
5VCap R U5 PBSw gag pol env PPT
U3 R Poly A 3V
Synthesis of a viral double-stranded DNA from this mole-
cule is required for integration to occur (Fig. 1).
Of note is that LTR regions in their entirety, which are
required for integration and for production of virus RNA, areonly present in the provirus (DNA copy) after reverse tran-
scription. Furthermore, of importance for vector design, it
should be noted that the U3 region found at the 5Vend of the
integrated provirus is derived from the 3Vend of the virus
RNA.
2.2. Lentivirus
The group of lentiviruses includes the primate retrovi-
ruses, human immunodeficiency virus 1 and 2 (HIV-1, -2)
and simian immunodeficiency virus (SIV). Nonprimate
lentiviruses are feline immunodeficiency virus (FIV),
bovine immunodeficiency virus (BIV), caprine arthritis-
encephalitis virus (CAEV), equine infectious anemia virus
(EIAV) and visnavirus. Lentiviruses have a tropism for
macrophages and lymphocytes, and share similar genome
organization and replication cycle. Lentiviruses are ‘com-
plex’, possessing additional regulatory domains that are
important for several stages in the replication cycle of the
virus. The search for treatment of HIV-1 infected patients
strongly stimulated research on HIV-1 biology. HIV-1
encodes six accessory genes: vif, vpr, vpu, tat, rev and nef
(Fig. 3). Of those, only rev and tat are strictly required for
virus replication. The other four accessory genes are asso-
ciated with HIV-1 virulence and other properties.
The integration phase of the lentiviruses life cycle differs
from the simple onco-retroviruses primarily in the fact that
the pre-integration complex may be more stable and in the
fact that this complex can cross the intact nuclear mem-
brane. This will be discussed further below in Section 3.1.1.
The virus production/assembly part of the life cycle of
lentiviruses also differs significantly from simple retrovi-
ruses. The LTR of the integrated provirus genome of both
simple and complex retroviruses directs the production of a
full-length RNA virus genome. Splicing of a subset of this
full-length RNA is an important part of the process of
producing a number of smaller mRNAs that more effi-
ciently direct the production of the basic structural and
enzymatic components of the final assembled virus (matrix
and nucleocapsid proteins derived from the gag; RT,
protease, and integrase derived from the pol; and envelope).
As will be discussed further below, this splicing function
must be considered in the design of efficient gene therapy
vectors from retroviruses. With complex retroviruses, this
process entails additional features. For example, HIV-1
gene expression can be divided into an early regulatory
and a late structural phase. In the early phase, multiple
spliced transcripts encoding the regulatory proteins tat, rev
and nef are produced. Tat then acts as a strong trans-
activator by binding to a stem-loop structure called TAR
(tat responsive element) that increases transcription of the
HIV genome. As rev accumulates, it interacts with RRE
(rev responsive element) on unspliced and incompletely
spliced viral transcripts and facilitates their nuclear export.
This facilitates accumulation of late accessory proteins vif,
vpr, vpu plus those structural and enzymatic proteins shared
Fig. 1. Reverse transcription (synthesis of viral double-stranded DNA) from single-stranded retroviral RNA. Reverse transcription is initiated by the binding of
specific tRNA(s) from the host cell to the virus RNA primer binding site (PBS) where DNA synthesis extends from the tRNA (acting as a primer) to the 5Vend
of the virus RNA template, thus copying the U5 and R region at that end (A). This creates a short DNA minus-strand that still contains the tRNA at its 5Vend.
This process is closely associated with degradation of the part of the template RNA that has just been copied (RT also has RNase H activity) except for the PBS
region, which is protected by the tRNA binding. The R region of the newly synthesized DNA minus-strand is then free to align with the complementary 3VR
region of the partially degraded RNA template (B). This alignment may be aided by the affinity of the RT for the 3Vend of the RNA template as well as other
factors. Synthesis of the DNA minus-strand then proceeds through the PBS region. As before, the reverse transcription is accompanied by degradation of the
remaining RNA template, except for an RNase-resistant polypurine tract (PPT) that will serve as the primer for synthesis of the plus-strand DNA through its
PBS region (C). The tRNA is cleaved from the minus-strand during the synthesis of the plus-strand PBS region. The next step involves the noncovalent
circularization of the DNA minus-strand mediated by the complementary pairing of the PBS regions of both strands, which includes the loss of the PPT at the 5V
end of the plus-strand (D).This now allows DNA synthesis of both strands to go to completion. Extension of the minus-strand from its 3Vend displaces its own
5Vregion from the plus-strand, thus allowing this region of the minus-strand to become the complement for completion of synthesis of the plus-strand (E).The
final result of this complex synthesis is a double-stranded DNA pre-integration complex with identical terminally redundant long terminal repeat (LTR)
elements (U3-R-U5) on both ends (F). This form of the virus has the capacity to insert into the cellular genomic DNA where it becomes a stably integrated
provirus capable of producing virus RNA copies. The integrated provirus form has the structure: U3-R-U5-PBS-w-gag-pol-env-PPT-U3-R-U5.
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integrase) and env as noted above.
2.3. Spumavirus
Spumaviruses represent one of the three major subfami-
lies of retroviruses. Human foamy virus (HFV) is the
prototype virus of this virus family and is thought to be
nonpathogenic to humans. As complex viruses, spumavi-
ruses encode gag, pol and env genes and in addition
structural regulatory genes. For example, HFV encodesbel-1 (Tas), -2 and -3. An internal promoter within the
env directs transcription from the bel-1 gene. Bel-1 is a
transcriptional trans-activator that promotes both LTR and
its own transcription and is essential for virus replication.
Bel-2 and bel-3, however, are dispensible for vector design.
In contrast to other retroviruses where the open reading
frames (ORFs) of gag and pol overlap in the same mRNA,
in this group, a spliced mRNA is produced that directs
synthesis of pol independently [8]. Another unique feature
of this group of retroviruses is that a subset of virus particles
contain full-length double-stranded DNA. It appears that in
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infection of the target cells [9]. This feature may contribute
to the properties of vectors derived from this group. As with
the lentivirus group, the interest in this group of retroviruses
for gene transfer application was promoted through the
findings of foamy virus expression in nonproliferating cells.3. Vector design
3.1. Issues affecting retrovirus vector performance
Transfer vectors have been engineered from retrovirus,
adenovirus, adeno-associated virus (AAV), herpesvirus,
Epstein–Barr virus (EBV), poxvirus and others. Where
high gene transfer efficiency is required, the use of virus
vectors is preferred to the physical methods of transfection
or electroporation of plasmid DNA into cells. Retrovirus-
based vectors are particularly attractive for treatment of
genetic diseases where stable long-term integration in the
genome is required. Furthermore, in clinical settings, retro-
viruses appear to have the lowest toxicity profile. For
example, while adenovirus vectors are extraordinarily effi-
cient at infecting a variety of cells and inducing production
of high amounts of protein, these vectors do trigger immune
responses (which for cancer treatment might be desired),
and do not efficiently integrate into the host genome. While
AAV may integrate, there appears to be a restricted group of
tissues in which this vector is particularly effective (e.g.
neural tissue or muscle, but not HSCs).
For these reasons, the onco-retrovirus vectors are highly
represented in clinical gene therapy trials for genetic dis-
orders (particularly for targeting hematopoietic cells such as
stem cells or T lymphocytes). For the cure of these diseases,
the ideal vector would integrate into the host genome of
long-term repopulating cells and would express its transgene
for the entire life span of the cell and its progeny without
toxic or immunogenic effects. However, retroviruses do
present certain problems that will be discussed under the
headings below.
3.1.1. Integration
The simple onco-retroviruses are dependent on cell
division for the genome integration phase of their infection
cycle because the pre-integration complex cannot penetrate
the nuclear membrane until the membrane is disassembled
during mitosis [10,11]. Replication-incompetent vectors
engineered from this group of viruses share this trait. In
rapidly dividing cells, integration of onco-retrovirus DNA
into the target genome may be first detected 4–7 h after
infection [11,12]. When cells were reversibly arrested in G2
for 20 h after infection with murine leukemia retrovirus,
integration still occurred when the cells were subsequently
released from cell cycle arrest, indicating some stability of
the pre-integration complex in the cytoplasm. Unintegrated
retroviral DNA in the nucleus exists as a linear form and ascircles. Only linear DNA integrates into the genome. While
the circular forms do not integrate, they may transiently
contribute to transgene expression falsely increasing the
apparent rate of transduction in the first few days after
infection [13].
While lentivirus pre-integration complexes most effi-
ciently enter the nucleus during mitosis, they also can
traverse the intact nucleus membrane of some nondividing
cells. The HIV-1-derived lentivirus vector (lentivector) pre-
integration complex is actively transported through the
nucleopore upon recognition of the nuclear localization
signals on matrix protein, vpr (one of the regulatory com-
ponents of this ‘complex’ retrovirus) and integrase by the
nuclear import machinery [14]. Hence, lentivectors appear
to stably transduce quiescent, terminally differentiated neu-
rons and nonproliferating monocytes [15,16]. Hemato-
poietic cells, however, are heterogeneous with respect to
their susceptibility to lentivector transduction. For example,
for T lymphocytes arrested in the G1a phase of the cell cycle
(defined as intermediate RNA level, single diploid DNA
copy and treatment with n-butyrate), HIV-1 lentivector
reverse transcription is initiated but cannot be completed.
Progression through G1a and arrest in cell cycle phase G1b
(defined as RNA levels equivalent to S-phase prior to DNA
synthesis and blockage through aphidicolin), however,
allows complete HIV-1 DNA synthesis [17]. Partial reverse
transcription can be rescued at later times upon mitogenic
stimulus. Thus, there may be factors other than nuclear
membrane transport in nondividing cells, such as nucleotide
substrate levels or DNA repair activity that may influence
the capability of lentivectors to integrate. However, as with
murine retrovirus vectors, the lentivirus vector pre-integra-
tion complex is labile and requires a close temporal relation-
ship between infection and subsequent integration [18].
Consistent with these data are results from several groups
demonstrating the poor transducibilty of human HSCs in GO
(defined by low RNA and single diploid DNA content) with
HIV-1-based vectors [19,20]. It has become customary to
compare the transduction rates of lentivectors and the simple
onco-retrovirus vectors under conditions in which cells are
unable or prevented from entering the cell cycle [19,21,22].
In general, the transduction rates of lentivectors improve
significantly when cells are released from cell cycle inhib-
ition or stimulated with growth factors to progress through
cell cycle, with highest transduction rates occurring in the S/
G2/M cell cycle phase.
Cancer development generally has been shown to require
a series of DNA changes (multiple hits), but it has been long
observed that replication-competent retroviruses (RCRs)
can induce cancers in a variety of model systems [23–
25]. In theory, tumorigenesis can result from multiple
retrovirus insert changes in a single cell, or may evolve
from a single insert that results in proliferative events that
enhance the probability that secondary changes occur in
subclones. In favor of the latter hypothesis is that insert
analysis of experimental tumors resulting from infection
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bility of a single insertional mutagenesis event (oncogene
activation) from retroviruses or retrovirus vector integration
to contribute to evolution of a malignant phenotype has
been estimated to be 10 7 [26]. Gene therapists are well
aware of the potential risk of insertional mutagenesis from
replication-incompetent retrovirus vectors. However, until
recently, no cancer has been attributed to replication-incom-
petent retrovirus vectors used over more than a decade of
clinical gene therapy studies. In August 2002, a successfully
treated X-linked severe combined immunodeficiency (X-
SCID) patient from the French trial of gene therapy for X-
SCID was diagnosed with a monoclonal T cell leukemia 30
months after treatment [4,6]. Using the method of linear
amplification mediated PCR (LAM-PCR), one vector insert
copy was detected in the leukemic T cell clone and mapped
to the first intronic sequence of the LMO-2 locus on the
short arm of chromosome 11. Aberrant expression of LMO-
2 was demonstrated in the leukemic clone despite the fact
that the insert was inserted in an orientation inverse to the
gene, suggesting that activation of this gene may have
occurred through effects of insert enhancer elements. The
frankly leukemic clone also demonstrated a t(6:13) chromo-
somal translocation, suggesting that secondary events con-
tributed to evolution to leukemia in this patient (http://
www4.od.nih.gov/oba/RAC/X-SCID.htm). In favor of this
hypothesis is that the investigators were able to find in
earlier archived blood samples a relative overexpression of
the clone containing this insert, but without the transloca-
tion. The clone expanded over time with transition to frank
leukemia being associated temporally with the appearance
of the chromosomal translocation. In December 2002, a
second case of leukemia occurred from among those four
engrafted patients of the first five reported X-SCID gene
therapy patients showing clinical correction of immune
function. The vector copy insert in this second patient’s
leukemic cells was found to be in the forward orientation
about 3000 bp upstream of exon 1 of the LMO-2 gene near
the start of the putative promotor for this gene. As in the first
patient, aberrant expression of LMO-2 protein was noted in
the leukemic clone. Also, as in the first patient, there were
other chromosomal changes that appeared at time points
later than the retrospective first detection of expansion of T
cells containing the LMO-2-associated insert (presentation
by Dr. Christof von Kalle at the NIH Office of Biotechnol-
ogy Activities, special Recombinant DNA Advisory Meet-
ing of February 10, 2003). It is of note that human T cell
leukemias have been reported previously in association with
aberrant expression of LMO-2 [27]. This association of two
independent leukemic events in two patients with inserts
associated with LMO-2 suggests that the leukemogenesis in
both patients shared a common mechanism and is not
random. It is possible to speculate that vector inserts that
activate aberrant production of LMO-2 protein confer a
major growth advantage in addition to the intended growth
advantage provided to T cells and T cell precursors in the X-SCID patient by transduction mediated expression of nor-
mal transgenic common g-chain. The significance of this
will be discussed further below.
It is of note that there was also the first report of leukemia
in a mouse induced by replication-incompetent retrovirus
vector insertional mutagenesis occurring in the first exon of
the Evi1 gene. In this case, the insert was inserted in the
same orientation as the affected gene where activation of the
gene likely occurred through the action of both LTRs. This
vector contained the truncated nerve growth factor receptor,
which the authors speculate has the capacity to interact with
and possibly activate tyrosine kinase receptors for neutro-
phins. Thus, in this report, it might have been the combi-
nation of an unexpected interaction of the transgene together
with the insertional activation of Evi1 that caused the
leukemia. In the reported studies, the leukemia clone was
shown to be transplantable to multiple mice [28]. It is
possible to speculate that the events in the X-SCID patients
may have been analogous to this mouse study in that the
transgene itself may function as an unregulated growth
factor serving as one of the ‘‘hits’’ in a ‘‘multihit’’ require-
ment for genesis of leukemia. We will comment further
about this below. In another animal study report, integration
of a retrovirus vector was found in one allele of the tumor
suppressor gene BRCA1 (breast cancer 1) in human non-
obese diabetic-severe combined immunodeficient (NOD/
SCID) repopulating cord blood cells [29]. It is not known
if this type of BRCA1 insert in a single allele would have
physiologic consequences in vivo in humans. However,
together with the other reports, it points out that initial
estimates of the frequency of retrovirus vector insertion in
sensitive sites may be underestimated. The generally held
belief that retroviruses integrate randomly into the genome
is questioned by a recent report that HIV favorably integra-
tes into active genes [30]. Thus, the sites of retrovirus
integration are likely to be associated with both the acces-
sibility of active sites of the genome and the transcription
activity status of a particular gene at the time of integration.
This makes it currently impossible to predict rates of
insertion at specific sites. Information about rates of inser-
tions near specific sites first must be obtained experimen-
tally with replication-incompetent retrovirus vectors to
begin to decode these patterns. On the other hand, as more
is understood, it may be possible in the future to deliberately
target to ‘‘safe’’ insertion sites to reduce the risk of adverse
effects. Furthermore, even without being able to guide
targeting of integration, if we assume and determine that
specific integration hotspots exist for certain applications,
an individual risk assessment before treatment is conceiv-
able.
Given the recent reports about the detection of insertional
mutagenesis, one may ask why over more than a decade
with human clinical trials and numerous studies using mice
and large animals, no such incidents were seen. In most of
these studies, the engrafted gene modified stem cell dose
was very small (less than 100 vector insert copies per patient
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followed longer than 1 year. Thus, the overall number of
vector insert-years followed in large animals or people is
relatively low and a long latency period may be required
(almost 3 years in the case of the two X-SCID gene therapy
patients who developed leukemia). However, it is likely
more than coincidence that two cases of leukemia are now
seen in the very small number of X-SCID gene therapy
patients treated worldwide (total treated X-SCID patients
estimated at over a dozen), and that in both cases, there was
an LMO-2-associated vector insert in the leukemic clones.
Not only does this suggest a nonrandom common biological
mechanism, but it raises the possibility that either the X-
SCID phenotype or the unregulated expression of the
corrective gene (common g-chain of the IL-2 receptor)
plays a critical role in the genesis of these leukemias. More
specifically, tumor formation in the X-SCID patients might
have been favored by the fact that the common g-chain
transgene is itself a growth factor that confers a strong
selective growth advantage to the corrected cells and thus
itself might promote tumor growth. There may also have
been a failure of tumor surveillance in X-SCID patients,
which remain relatively deficient in NK cells. In any case,
these considerations make it very difficult to extrapolate the
significance of these adverse events in the X-SCID gene
therapy to other applications of retrovirus-mediated gene
therapy.
3.1.2. Silencing
Transgene expression is influenced by the effects of
chromosomal sequences adjacent to the integration site
and is strongly correlated inversely with CpG methylation.
Vector integration into, or next to heterochromatin may
induce inhibition of transcription (position-dependent
silencing) or may result in varying expression in progeny
cells (position-effect variegation) [31]. Transcriptionally
active and inactive chromatin inevitably lie adjacent to each
other and within these boundaries, sequences have been
identified that act as a neutral barrier to influences from
neighboring regulatory elements [32]. The best-described
insulator in vertebrates is cHS4—the chicken hypersensitive
site 4. Flanking an onco-retroviral transcription unit with
cHS4 greatly decreases transgene silencing in mouse bone
marrow cells [33]. Rivella et al. [34] demonstrated in murine
erythroleukemia cells that increased probability of transgene
expression was strongly associated with less LTR methyl-
ation in transgenes carrying the cHS4 insulator. However,
the amount of expressed transgene varied among positive
clones. Furthermore, the positive insulator effect was not
seen in embryonic stem cells—lack of expression was
accompanied with LTR methylation.
It is commonly agreed that gene silencing tends to occur
in undifferentiated cells that go through a long differentia-
tion process. As noted above, CpG methylation is strongly
correlated with gene silencing. Regions rich in nonmethy-
lated CpGs are found in many functional promoter elements.Integration of foreign DNA sequences into the genome itself
triggers methylation of CpG dinucleotides. DNA methyla-
tion inhibits transcriptional activity. A link between DNA
methylation and chromatin structure has recently been
identified. By binding to methylated viral sequences, host
proteins mediate the recruitment of histone deacetylases
(HDAC) to the transduced gene locus. HDAC deacetylate
specific histones and lead to chromatin condensation and
transcriptional silencing [35,36]. In an attempt to achieve
higher long-term transgene expression, Robbins et al. [37]
modified the LTR region of the Moloney MLV-based vector.
According to their data, the insertion of the hypomethylation
signal from the mouse Thy-1 gene into the U3 region of the
5VLTR—among other modifications—helps to protect the
vector from de novo methylation and leads to increased
gene expression in secondary CFU-S after serial transplan-
tations with transduced bone marrow in mice. However,
some investigators have questioned the degree to which
silencing of murine onco-retrovirus vectors in murine cells
is as significant when these vectors are used in human cells.
Transgene expression from a lentivirus vector in murine
embryonic stem cells was shown not to be affected by
silencing [38]. Silencing, however, depends on the target
cell type and may vary over time. Thus, there will be no
definite answer to whether transgenes introduced by lenti-
virus vectors will be silenced in people until the first such
clinical trial takes place.
3.1.3. Selective advantage conferred by vector transduction
The success of human gene therapy trials is limited in part
both by the resistance of human stem cells to stable genetic
modification and by the degree to which genetically altered
cells may replace resident uncorrected cells. The recent
achievement of long-term marking of transduced hemato-
poietic cells in large animals demonstrates the feasibility of
relatively stable high-level HSC marking [39–41]. However,
for most applications, the percentage of transgene-positive
progenitor cells is too low for clinical benefit. Furthermore,
achieving these higher levels of stable long-term marking in
general seems to require ablation of resident untransduced
marrow stem cells. In vivo selection for transduced progen-
itors has the potential to dramatically increase the percentage
of transgene-positive cells and might compensate for the low
transduction efficiency of the long-term repopulating stem
cells. As demonstrated in a gene therapy trial for patients
with X-SCID, transduction of human CD34+ HSCs with
vector expressing the common g chain of IL2, IL4, IL7, IL9,
IL15 and IL21 receptors confer an in vivo growth advantage
for certain lymphoid progenitor cells, and thus fully repopu-
late the T cell compartment despite relatively low trans-
duction efficiency and very low levels of marking in the
myeloid cell compartment. Of further note is the marking of
B-lymphocytes in 1–2% [2,3]. In that study, the marking of
myeloid cells was only 0.01–0.1%, demonstrating both the
continued difficulty of gene marking and engraftment of
HSCs without marrow conditioning regimens, but highlights
Fig. 2. DNA repair from alkylating agents. O6-BG inactivates wild-type
AGT, while mutant AGT is resistant to O6-BG and allows DNA repair from
alkylating agents (Temozolomide, TMZ).
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cytes. For gene therapy for adenosine deaminase (ADA)-
SCID, the selective growth advantage provided by gene
therapy to T lymphocytes did not appear to be sufficient to
provide clinical benefit [42,43]. However, a recent study of
gene therapy for ADA-SCID employing significant bone
marrow conditioning with busulfan resulted in significant
marking of myeloid cells (up to 10%) and up to 90%marking
of T lymphocytes with normalization of T lymphocyte
function and counts at 1 year after gene therapy [1]. This
study demonstrates that marrow conditioning may enhance
engraftment and therefore gene therapy marking even where
no or low selective advantage is expected (the myeloid
compartment) and at the same time may enhance a selective
advantage where one is expected (T lymphocytes). It should
be noted that these patients did not receive enzyme replace-
ment therapy, which might also have contributed to the T
lymphocyte growth advantage [44]. Since most immune and
metabolic disorders do not provide a selective advantage to
genetically corrected cells at either the stem cell level or at
the level of differentiated cells, elements conferring selective
advantage are being engineered into vectors. Expression of
drug resistance genes such as the multidrug resistance gene
(MRD1) that encodes P-glycoprotein, render tumor cells
inaccessible to certain anticancer drugs. The mechanism of
this adverse effect can be harnessed to achieve selective
growth advantage for either protecting HSCs from chemo-
therapy during transplantation or for genetic correction
purposes. The introduction of a selectable marker, such as
a chemoresistance gene into donor cells, protects against the
respective chemotherapeutic drug and might result in a stable
enrichment of modified progenitor cells. Bicistronic vectors
containing both a selectable marker and a reporter or
therapeutic gene in the same mRNA allow artificial selection
in gene therapy. Here the co-expression of two transgenes in
a single transfer vector can be established by insertion of a
picorna virus internal ribosome entry site (IRES) between
both genes [45]. Examples of selective markers tested for
their enrichment capabilities are genes encoding dihydrofo-
late reductase (DHFR), MDR1, multidrug-resistance-associ-
ated protein transporter, glutathione-S-transferase, aldehyde
dehydrogenase or O6-alkylguanine-DNA-alkyl-transferase
(AGT).
Transduction with a human DHFR mutant gene confers
drug resistance for antifolates such as methotrexate (MTX)
or trimatrexate. However, repopulating stem cells can
import nucleotides from the serum and thus are resistant
to antifolate-induced inhibition of de novo purine and
thymidine biosynthesis. A combination therapy of the
thymidine transport inhibitor nitrobenzylmercaptopurine
riboside (NBMPR) and MTX results in cell death of non-
transduced repopulating stem cells, but transduced cells are
resistant to this dual therapy [46].
Transduction of cells with the MDR1 confers protection
from various toxic drugs such as vinca alkaloids, anthracy-
clines and colchicine. The calcium channel blocker verapa-mil is an inhibitor of the MDR1-encoded P-glycoprotein and
thus can reverse the MDR1-induced drug resistance. Several
studies have examined whether transplantation of MDR1-
transduced progenitor cells allows selection and resistance
to treatment with these chemotherapy agents [47,48]. Bunt-
ing et al. [49] reported the development of a myeloprolifer-
ative disorder in mice transplanted with MDR1-transduced
bone marrow cells, but such adverse consequences have not
been reported by others, nor seen in any of the human trials
with MDR1. In the Bunting et al. study, the transduced cells
were subjected to prolonged ex vivo culture and this may
have contributed to the adverse outcome. To date, clinical
trials with MDR1-transduced HSCs have not demonstrated
the desired selective enrichment to a degree that might
provide clinical benefit; however, it has recently been
demonstrated that MDR1 can confer chemoresistance in
vivo in mice transplanted with MDR1-transduced HSCs
[50–52].
Different human cells express various levels of the DNA
repair protein AGT. The O6-methylguanine-DNA-methyl-
transferase gene (MGMT) encodes for AGT. AGT protects
cells from alkylating agents including nitrosoureas and
temozolomide by repair/removal of O6 adducts prior to
DNA cross-link formation (Fig. 2A). The chemical reactions
associated with catalytic DNA repair inactivate AGT and
therefore the resistance of a cell to treatment with an
alkylating agent is dependent upon the initial levels of
active AGT in the cell [53]. O6-benzylguanine (6-BG) can
act as a substrate for the enzyme, becoming a potent
irreversible inhibitor of AGT (Fig. 2B). This biochemical
property of this repair enzyme has been used to design a
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retrovirus vectors. Several mutant forms of MGMT give
rise to altered AGT enzymes that are highly resistant to 6-
BG, but retain their ability to repair DNA damage from
alkylating agents (Fig. 2C) [54–58]. The most interesting
one appears to be the AGT P140K mutant, which is almost
completely resistant to 6-BG (greater than 200 AM), while
only showing a 4- to 10-fold reduction in the rate of
methylated DNA repair compared to wild-type AGT
[55,56,58]. Also of interest has been the AGT G156A
mutant that is 60- to 240-fold more resistant to 6-BG than
wild type with only a 13- to 25-fold reduction in rate of
DNA repair. The cancer chemotherapy agent BCNU kills
dividing cells by alkylating DNA. Even in quiescent HSCs,
the cross-links lead to cell death once these cells start to
proliferate, unless repair takes place. Resistance to BCNU is
strongly correlated with cellular levels of active AGT.
Treatment with 6-BG can be used to lower the cellular level
of AGT, greatly increasing the susceptibility of cells to the
toxicity of BCNU. When cells are provided with the means
of producing mutant AGT resistant to 6-BG by transduction
with a retrovirus vector containing mutated MGMT, then the
cells become resistant to the BCNU-sensitizing effects of
treatment with 6-BG. The protection seen in culture systems
also has been demonstrated in mice in vivo. Nonmyeloa-
blative-conditioned mice were transplanted with murine
bone marrow progenitor cells transduced with onco-retro-
virus vector MFG containing an MGMT mutant encoding
AGT G156A. Subsequent treatments with two cycles of 6-
BG with BCNU enriched the percent of transduced progen-
itors in the marrow of these animals such that at 2 months
after transplant, nearly 100% of colony-forming cells from
the marrow of these animals contained the mutant MGMT
transgene [59]. More recent data from Sawai et al. [60]
using the P140K variant support these promising results.
However, concern that could arise when considering clinical
application of this selection approach is that the combina-
tion 6-BG plus BCNU may be so potent that unless true
permanently repopulating stem cells are transduced, there is
a theoretical danger that the resident stem cell population
could be eliminated, and support of hematopoiesis by
transduced medium-term repopulating stem cells may
diminish over time. Thus, initial ‘‘success’’ over several
months might be followed by late marrow failure. Hema-
topoiesis from few stem cell clones would demand a faster
proliferation rate of the contributing stem cells, increasing
the probability of chromosomal instability and other muta-
genic events, or their earlier senescence from effects such as
telomere shortening [61,62]. The solution to this problem is
to assure that transduction efficiency is improved to the
point where there is high confidence that a large number of
totipotent permanently repopulating stem cells are trans-
duced and express mutant MGMT. In addition, other cells
such as lung tissue would not be protected by mutant
MGMT and would be more susceptible to BCNU toxicity
after treatment with 6-BG.The risks of such a selection regimen might be mitigated
by employing a positive growth signal. This could provide
the selective growth advantage to transduced HSCs without
the risk of completely eliminating the resident nontrans-
duced population. Recently, a novel approach to providing a
selective growth advantage to transduced cells has been
described. Ito et al. [63] constructed a chimeric transgene
consisting of the signal-transducing domain of the G-CSF
receptor fused to the hormone-binding domain of the estro-
gen receptor. This construct conveys a proliferation signal
upon estrogen (but not G-CSF) administration and was used
successfully to selectively expand transduced hematopoietic
cells in vivo in a nonhuman primate model [64]. Though
there are potential problems with this particular fusion
protein (chronic treatment with estrogen and the unknown
effects of the G-CSF receptor signaling), this is an encour-
aging general concept. It may be possible to find an
optimum intracellular growth-signaling moiety requiring
dimerization for signaling, and linking it to an extracellular
domain that is designed to bind only to an otherwise
biologically inactive bivalent drug.
For applications where HSCs have to be cultured ex vivo
prior to transplantation (e.g. ex vivo transduction with
retrovirus vectors for gene therapy) or where the number
of HSCs is not sufficient for transplantation (e.g. use of cord
blood), ex vivo expansion by self-renewal of true stem cells
would be desirable. Attention has recently focused on the
overexpression of the homeobox gene HOXB4. Introduc-
tion of HOXB4 into murine HSCs by a retrovirus vector
allowed ex vivo expansion and a 40-fold net increase of
marrow-reconstituting cells, while the potential of in vivo
lympho-myeloid differentiation was preserved [65]. Similar
expansion results could be achieved with retrovirus-vector-
mediated HOXB4 overexpression in human cord blood
cells; however, impaired differentiation was seen with high
levels of HOXB4 transgene expression [66]. Thus, the level
of HOXB4 expression seems to alter the fate of HSCs in a
concentration-dependent manner. Since HOXB4 is a
growth-promoting factor, this would be best used in a
transient expression system and with control elements that
would allow careful regulation of expression level.
For some kinds of gene therapy applications, the goal
may be to kill the transduced cells in vivo after those cells
have performed the required task. An example might be the
use of transduced allogeneic lymphocytes to achieve stabil-
ity of an allogeneic stem cell graft, but with the potential of
eliminating these lymphocytes if significant graft versus
host disease emerges. Transfer of herpes simplex virus
thymidine kinase (HSV-tk) as a ‘suicide gene’ into target
cells allows for negative selection using the otherwise low
toxicity pro-drug, ganciclovir. In allogeneic bone marrow
transplantation, the donor lymphocytes are responsible for
host immune reconstitution as well as establishment and
maintenance of donor cell engraftment. In the setting of
leukemia or other cancer, these allogeneic donor lympho-
cytes are also required for elimination of the leukemia or
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T lymphocytes is graft-versus-host disease (GvHD). Bonini
et al. [67] demonstrated, using an onco-retrovirus vector to
deliver HSV-tk to donor peripheral blood lymphocytes, that
this approach allows effective elimination of donor T
lymphocytes following gangciclovir administration. This
was associated with elimination of clinical manifestations
of graft versus host disease in two of three patients and some
clinical improvement in the third patient. For this approach
to be most successful, it would be best if all nontransduced
lymphocytes could be eliminated from the graft. In one
study, this was accomplished by co-expression in the same
vector of a cell surface marker that could be used for
positive selection of only transduced donor lymphocytes
ex vivo prior to infusion of these lymphocytes into the
recipient. Alternatively, co-expression of an in vitro select-
able element such as the neomycin resistance gene could be
used for the same purpose [68]. Transduced T lymphocytes
(to 90% gene modified cells) were selected by G418-
containing cell culture medium for 7 days to eliminate the
untransduced population. Two of three patients treated with
these cells and experiencing acute GvHD responded with
complete remission of the GvHD after ganciclovir treat-
ment. One patient with chronic GvHD showed complete
resolution with ganciclovir plus intravenous immunoglobu-
lin infusion. The latter was given due to occurrence of
hypogammaglobulinemia. Three of the total 12 patients
enrolled in this study developed EBV lymphoproliferative
disease (EBV-LPD) after allogeneic bone marrow trans-
plantation using a T lymphocyte depleted stem cell graft
supplemented with the gene-modified T lymphocytes.
Although EBV-LPD is a known complication of allogeneic
BMT, the authors could not rule out that the high number of
positive cases occurring in this study were a result of
restricted development of immunocompetence by ex vivo
cultured T lymphocytes.
An alternative ‘suicide gene’ selective system that has
been incorporated into a retrovirus gene therapy approach to
treatment of GvHD relies on the use of an artificial Fas-
mediated suicide switch in the targeted donor T lympho-
cytes. Cross-linking of Fas, a member of the tumor necrosis
factor receptor superfamily induces apoptosis. Thomis et al.
[69] built upon the work of Spencer et al. [70] to engineer a
complex chimeric transmembrane protein consisting of the
extracellular and transmembrane domains of the human
low-affinity nerve growth factor receptor fused to a tandem
repeat of the binding domain of the F36V-mutated FK506-
Binding Protein (FKBP12), and ending with the intracellular
domain of Fas. Retroviruses and retrovirus-derived vectors
have a relatively high tendency to experience recombination
events when repeat elements are present. To prevent such
recombination, these investigators changed the codons of
the cDNA encoding the first of the tandem mutant FKBP12
domains at sites that would not alter the amino acid coding.
Furthermore, the mutation in these FKBP12 elements allows
binding only to the synthetic bivalent drug AP1903 (devel-oped specifically for the purpose of creating an artificial
dimerization tool) and not to its natural ligand [71]. The
extracellular domain allows selection of only transduced
lymphocytes ex vivo, while the tandem mutant FKBP12
domains allow a means of efficiently dimerizing the mole-
cule, and the Fas domain stimulates apoptosis when dimer-
ized. A final advantage to the AP1903/Fas system is that all
of the portions of the chimeric transgene are of human
origin, so that immune responses should be minimal.
Furthermore, the authors suggest that the Fas-based suicide
switch may also work independently of cell cycle, allowing
the elimination of slowly dividing T cells. This concept of
artificial induction of dimerization can also be applied to a
positive growth regimen, where the intracellular signaling
domain is derived from growth factor receptors such as the
thrombopoietin receptor that confers positive selection upon
addition of the chemical inducer of dimerization [72,73].
3.1.4. Inactivation barriers to in vivo vector administration
Most clinical trials of gene therapy using retrovirus
vectors have employed the ex vivo approach, in which the
target cells such as HSCs or tumor cells (for immune
stimulation) are transduced outside the body. The alternative
approach of direct in vivo administration of onco-retrovirus
vectors has been hampered by the fact that vectors produced
from murine producer cell lines are subject to inactivation
by human serum complement [74]. This inactivation results
from complement fixation related to surface antibody bind-
ing to certain carbohydrates that are present in murine cells,
but are not present on human cells. Humans, apes and Old
World monkeys lack a functional (a1–3) galactosyl trans-
ferase gene and therefore do not possess the carbohydrate
structure a-galactosyl (galactosyl [a1–3] galactosyl h1–
4GlcNAc-R) on their cell surface. However, cross-reactive
a-galactosyl-like epitopes exist on bacteria of human gastro-
intestinal flora and lead to production of natural antibodies
to a-galactosyl (anti-Gal) [75]. Pre-existing anti-Gal anti-
bodies in human serum bind to a-galactosyl and activate the
complement system resulting in lysis of virus generated in
murine producer cells [76,77]. It is possible to speculate that
these naturally existing anti-Gal antibodies in humans
probably help to restrict the transmission of mammalian
C-type retroviruses from other nonprimate animal sources.
This issue has stimulated the development of human cell
lines for packaging of retroviruses. It is of interest that even
for ex vivo transduction, where antibody and complement
effects should not be an issue, there appears to be improved
performance of vectors produced from such human pack-
aging lines.
Producer cell components are not the only cause of
inactivation of viral particles. Immunogenicity to the env
glycoprotein can cause viral vector inactivation, which has
been shown for the glycoprotein G of the vesicular stoma-
titis virus (VSV-G) envelope [78]. Despite these problems,
the ability to concentrate VSV-G-pseudotyped vector pro-
duced from human cell packaging lines may provide a
S. Brenner, H.L. Malech / Biochimica et Biophysica Acta 1640 (2003) 1–2410means of exploring the potential of in vivo gene therapy
using highly concentrated retrovirus vectors.
3.1.5. Virus vector binding to cells
All of the retrovirus vectors that are the subject of this
review have a glycolipid membrane envelope that contains
specialized proteins that engage specific receptors on the
target cells. The envelope proteins contain binding domains
that facilitate attachment to the target cell and trigger a
conformational change in membrane fusion facilitating
domains that catalyze fusion of the virus envelope mem-
brane to the membrane of the target cell. This virus envelope
protein binding to its receptor defines the infection spectrum
of the virus (animal species and cell types that can be
infected). Thus, a main limiting factor for successful gene
transfer is efficient binding of virus vector particles to cell
surface molecules with the associated vector transport
through the plasma membrane into the cytoplasm. For some
enveloped viruses, binding to the cell surface receptor is a
sufficient stimulus to the subsequent process of fusion of the
virus envelope to the cell membrane. In other cases, addi-
tional events must occur, such as acidification of the endo-
some for membrane fusion to take place.
To direct the virus vector to specific target cells or to take
advantage of the relative density of particular receptors on a
target cell, the virus vector can be encapsidated either by the
envelope protein native to the source of that vector or by the
envelope protein of a different virus (pseudotyping). The
majority of clinical human gene transfer trials targeting
HSCs have used MLV- or murine-sarcoma-virus-derived
vectors pseudotyped with either the MLV amphotropic
envelope or with the gibbon ape leukemia virus envelope
(GALV). The envelope protein of amphotropic retrovirus
binds to the sodium-dependent phosphate transporter pro-
tein Pit-2 (Table 1) [79,80]. Pit-2 is expressed on murine,
canine, nonhuman primate and human cells. Its relatively
low expression on murine HSCs and also on the more
primitive lineage-negative subset of human CD34+ cells
correlates with the relatively low efficiency of amphotropic
pseudotyped retrovirus transduction in these types of cells
[81]. A closely related phosphate transporter is Pit-1 that is
the receptor for GALV envelope protein [82–84]. Since
mouse cells lack the GALV receptor, GALV-pseudotyped
vectors cannot infect mouse cells. Of particular importance
with respect to gene therapy for hematopoietic disorders is
that both T lymphocytes and lineage-negative CD34+ HSCs
appear to have somewhat higher amounts of mRNA for
GALV than the amphotropic receptor and this appears to
correlate with better transduction efficiency with GALV
versus amphotropic envelope pseudotyped retrovirus vec-
tors. Of note is that the receptor for ecotropic MLV is the
murine cationic amino acid transporter, which is present in
high amounts on primitive murine HSCs [85,86]. A differ-
ence of two amino acids within the binding site of murine
and human cationic amino acid transporter allows binding
of ecotropic MLV to mouse cells but prevents any bindingto human cells, highlighting the degree of specificity that
can be conferred by pseudotyping. The receptor for the
endogenous feline type C virus RD114 and the simian type
D retroviruses is a neutral amino acid transporter [87,88].
This receptor is highly represented on human HSCs. Com-
parison of human CD34+ stem cell transduction with RD114
versus amphotropic envelope pseudotyped MLV demon-
strates remarkably higher efficiencies of transduction when
the same vector is pseudotyped with RD114. Furthermore,
RD114-pseudotyped virus particles in contrast to ampho-
tropic or GALV-pseudotyped virus particles can be concen-
trated by ultracentrifugation without loss of infective titer
[89,90]. This ultracentrifugation concentration of virus par-
ticles allows replacement of conditioned with fresh medium
and also allows enhancement of transduction of human
CD34+ HSCs beyond that achievable even with GALV
pseudotyped vectors. RD114 pseudotyped vectors cannot
infect murine cells, unless cells are treated with tunicamycin
(a inhibitor of N-linked glycosylation) [91]. This suggested
that the mouse receptor interaction with RD114 envelope
protein is blocked by a species-specific glycosylation. We
and others have found that RD114 pseudotyped vectors
achieve highly efficient transduction of nonhuman primate
and dog HSCs ex vivo, though the efficiency in these
species are less than the levels of transduction seen with
human HSCs ex vivo [92–94]. Thus, the RD114 envelope
pseudotype deserves consideration for use in clinical appli-
cations targeting HSCs.
HIV-based lentivirus vectors have attracted much atten-
tion for their potential to transduce nondividing cells. Since
most of the primitive long-term marrow reconstituting HSCs
are quiescent and are slow to enter the cell cycle even in
response to growth factors ex vivo, lentivectors have been of
particular interest for targeting these cells. Most lentivector
systems that have been developed rely on the use of VSV-G
because the receptor for the VSV-G envelope appears to be a
phospholipid moiety that is ubiquitous in all cells conferring
broad specificity to vectors pseudotyped with this envelope.
Furthermore, like RD114 pseudotyped vectors, the VSV-G
pseudotyped vectors can be effectively concentrated by
ultracentrifugation with minimal loss of biological activity
[95,96]. Following attachment of VSV-G particles, mem-
brane fusion occurs upon acidification of endocytic vesicles
[97]. Despite the ubiquitous presence of VSV-G receptor on
all cell types of all mammalian species and the potential to
concentrate VSV-G pseudotyped vector, the overall trans-
duction rates that can be achieved with such vectors, while
good, have not been extraordinarily high. Furthermore, there
is some cytotoxicity associated with VSV-G that limits the
concentrations of vector that can be used without reducing
target cell viability. This same toxicity of VSV-G has
hindered the development of stable vector packaging cell
lines that pseudotype vectors with VSV-G, though develop-
ment of packaging lines encoding inducible expression of
VSV-G have been reported [98]. For this reason, investiga-
tors have begun to explore the potential to pseudotype
Table 1
Examples of onco-retrovirus vector packaging cell lines






w CRIP [110] Amphotropic
(Pit1, phosphate transporter)
murine NIH3T3






FLYRD18 [74] RD114 (RDR, neutral
amino acid transporter)
human HT1080
PG13 [112] GALV (Pit2, phosphate
transporter)
murine NIH3T3
GP+ E86 [113] Ecotropic (CAT, cationic
amino acid transporter)
murine NIH3T3
S. Brenner, H.L. Malech / Biochimica et Biophysica Acta 1640 (2003) 1–24 11lentivectors with other envelopes such as RD114. Hanawa et
al. [99] were the first to report efficient pseudotyping of
lentivector with RD114 envelope. More recently, Sandrin et
al. [100] reported that successful pseudotyping with RD114
requires a modification of the carboxy-terminal end of the
envelope. These investigators fused the cytoplasmic tail of
the amphotropic glycoprotein to the transmembrane/extrac-
ellular domains of the RD114 envelope glycoprotein. This
modification resulted in enhanced transduction efficiency of
human CD34+ cells and lymphocytes compared to VSV-G or
GALV pseudotyping. The great potential of retroviruses to
accept packaging with a wide range of envelopes from
diverse virus groups has led to considerable research activity
devoted to exploring the potential of novel virus envelopes to
enhance both the cell type specificity and the overall target-
ing efficiency of retrovirus vectors. Thus, it is not possible in
this review to anticipate all developments in this rapidly
moving area. As an example, it has recently been shown that
envelope proteins from Marburg or Ebola virus can be used
to pseudotype retrovirus vectors [101]. Another approach to
the issue of conferring tropism in envelope pseudotyping has
been the use of molecular engineering to achieve novel
targeting by replacing virus envelope binding domains with
domains from ligands of human receptors or with the attach-
ment domains of antibodies that bind to human cell surface
receptors [102–108]. While novel specificities have been
achieved with such approaches, in general, it has been at the
cost of decreasing the effective overall transduction effi-
ciency. Nonetheless, these approaches deserve additional
attention.
3.2. Issues of the design of retrovirus vector systems
3.2.1. Onco-retrovirus vectors
The design of the onco-retrovirus vector system is based
on separating the ‘packaging’ elements from the transfer
vector. The term ‘packaging’ elements refers to plasmids
that express all the genes required to construct an intact
infectious virus particle (i.e. matrix, capsid, nucleocapsid,
RT, integrase, protease and envelope), but such constructs
generally lack the virus genomic elements that allow incor-
poration of the mRNA into the virus particle (i.e. they lack
the packaging signal called w). The transfer vector encodes
for production of an mRNA that contains the w packaging
sequence that is recognized by the packaging proteins for
incorporation into the virus particle. Thus, packaging cells
provide the helper function to enable assembly of the
replication defective virus. A variety of packaging cell lines
have been engineered from cell lines such as NIH3T3
(murine fibroblasts), 293 (human embryonic kidney cells),
HT1080 (human sarcoma cells) and many others by stably
transfecting with the onco-retroviral helper gag, pol and env
genes. Constitutive expression of their proteins is ensured
by positive selection for drug resistance genes, which are
linked to plasmid constructs that were engineered to encode
the virus packaging structural genes. Without the addition ofthe retrovirus transfer vector that provides mRNA contain-
ing the w element, these packaging cell lines secrete ‘empty’
virion particles. The first generation of onco-retroviral pack-
aging lines often contained a single plasmid packaging
element that consisted of the entire provirus with the w
packaging signal altered to prevent incorporation into the
virus particle. However, with such a system, one recombi-
nation event between the transfer vector and the packaging
element could restore the packaging signal, thus producing
an RCR. Subsequent generations of packaging plasmid
design focused on separation of the gag-pol coding regions
and the envelope coding regions into separate plasmids.
Furthermore, the 3VLTR was deleted and replaced by
polyadenylation signal sequence from nonretrovirus sources
(for example SV40). 5VLTR was either modified to further
cripple virus functions or replaced by alternate promoters
from nonretrovirus sources. The most modified of such
constructs require multiple and highly unlikely recombina-
tion events to create a RCR.
Table 1 gives examples of some commonly used stable
onco-retrovirus packaging cell lines with highly modified
packaging elements, where the gag-pol and env coding
sequences are contained on separate integrated plasmids.
This list is not meant to be complete, but illustrates the
variety of stable packaging cell lines in common use in the
laboratory, some of which have been used to generate vectors
for clinical trials. Transient packaging systems such as the
popular Phoenix line (based on the easily transfectable 293T
cell) are not included in this list. However, there is little
difference between the general design of packaging cell lines
that are used for ‘transient’ production of infective retrovirus
vector and those that are used to obtain stable ‘producer’
lines. With ‘transient’ production systems, virus vector is
packaged and exported to the medium for a short period of
time after the packaging line is transfected with the vector
plasmid that contains the w region and therapeutic/marker
gene of interest. The vector RNA is transcribed primarily
from nonintegrated plasmid DNA. Stable producer lines can
be obtained by selection and screening for packaging cell
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In general, stable producer lines can be found that secrete
higher titers of infective retrovirus vector into the medium
than can be obtained by transient production systems. The
general term ‘transient production’ has also been applied to
approaches to infective vector production in which easily
transfected cell lines—containing neither integrated pack-
aging elements nor the vector plasmid—are transfected
simultaneously with both the transfer vector plasmid and
all of the packaging element plasmids. This achieves a
transient burst of infective virus production. It is this type
of approach that has been used primarily where the pack-
aging elements have some toxicity (i.e. VSV-G).
It is important to note that in all of these systems, only
the transfer vector containing the nucleotide base pair
sequences that end up in the complete virus particle are
designed to retain the intact w sequence. As previously
indicated, the therapeutic or marker gene sequences of
interest are cloned into the transfer vector that is otherwise
devoid of virus structural genes and ideally is also designed
to minimize overlapping sequences with the packaging
constructs. The removal of such virus structural genes also
creates space for the inserted therapeutic/marker sequences,
which is important because there are limitations on the size
of vector RNA that can be packaged into the virus particle.
In search for enhanced transgene expression, improved
biosafety, and/or to provide a selective advantage, different
approaches to transfer vector design have been taken. The
simplest design consists of a single ORF of therapeutic or
marker gene inserted in such a way that following vector
integration in a target cell, the 5VLTR transcribes an mRNA
capable of translating the protein of interest.
Many of the earliest vectors incorporated a second potent
internal promoter (such as that from the SV40 virus) that
drove expression of a second mRNA from the same con-
struct. This approach has often been used to allow simulta-
neous expression of a therapeutic/marker protein together
with a protein conferring a selection advantage (i.e. neomycin
phosphotransferase conferring resistance to the neomycin
analog G418). In theory, the internal promoter also could
have special characteristics such as conferring tissue-specific
or other regulative transcription. One limitation of this
approach is that promoter competition may lower the level
of expression of mRNA from both promoters, but particularly
from the internal promoter. Furthermore, in the situation
where one of the gene products is a selection marker, it is
possible that under selection conditions only expression of
selection marker mRNA might be retained, while expression
of the therapeutic mRNAwanes or ceases.
One approach that has been devised to address both of
these problems associated with the use of two promoters in
the same vector is the creation of a bicistronic vector
incorporating an IRES. In place of a second promoter, the
IRES element is inserted between the two ORFs. With such
a design, only one mRNA transcript is produced by the one
functional promoter (usually the LTR). One protein istranslated from the first ORF in the conventional fashion
while the IRES element allows initiation of translation from
the second ORF through a mechanism not requiring the
usual ribosome attachment recognition signals [45]. The two
advantages of using an IRES compared to dual promoter
vectors is lack of transcriptional interference and the obli-
gate linking of both genes. This is particularly useful when
combining a therapeutic gene with a second gene providing
a selectable marker or growth advantage. Despite these
advantages, one problem is that translation of the second
protein derived from ribosomal interaction with the IRES is
lower than that of the first protein in the bicistronic mRNA.
In wild-type retroviruses, alternate splicing of the full-
length virus RNA is critical for the creation of smaller
mRNA species that more efficiently translate specific ORFs.
One particularly important example is the splicing event that
brings the virus envelope ORF much closer to the important
translation-enhancing sequences. However, it is only full-
length vector RNA sequence containing an intact w sequence
that is incorporated into infective virions by a packaging cell
line. Thus, to the extent that splicing occurs, there is a
reduction in virus titer obtained from a producer line. For
this reason, many of the early vectors were engineered to
remove splicing sequences to enhance virus titer. Retention
of splice donor sites in engineered vectors can sometimes
result in undesired splicing with cryptic acceptor sites found
in therapeutic proteins. This provided another reason for the
removal of splicing sequences from early transfer vector
designs. However, retention of certain splicing elements in a
transfer vector was found to greatly enhance protein pro-
duction in the target cell. Thus, the requirement for higher
virus titer obtained from the producer cell line appeared to be
in conflict with the desire for higher protein production in the
final target cell. This problem was partially solved by the
finding that certain splicing sites could be retained to
enhance protein production in the target cells, while still
obtaining a high titer of infective virus from selected stable
producer clones. It may be that such selected clones have
less-efficient splicing of the vector RNA than occurs in the
final target cell. One of the early examples of a highly
successful transfer vector design that retains splicing ele-
ments is MFG (MLV based) and its derivatives [114,115].
Another approach that has been used for enhancing
expression of a desired mRNA species from a transfer
vector is the invention of the ‘double copy’ vector design.
In this design, a heterologous promoter and transgene of
interest are inserted into the R or U3 region of the 3VLTR of
the vector plasmid. The creation of a ‘double copy’ from
this vector design relies upon the feature of reverse tran-
scription in which—proceeding integration into a target
cell—the 3V LTR serves as template for the 5VLTR synthesis
[116]. Thus, while this maneuver generates two transgene
copies, it inactivates the 5VLTR promoter activity. Inactiva-
tion of the 5VLTR has been the basis of the construction of
so-called ‘self-inactivating’ (SIN) vectors [117]. In such
vectors where the ‘double copy’ feature is not desired, it
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the U3 region of the 3V LTR of the transfer plasmid to
destroy 5VLTR function in the final integrated product. The
newer generation of lentivirus vectors have incorporated this
SIN feature as will be discussed below.
3.2.2. Lentivirus vectors
Gene transfer vectors engineered from the lentivirus
group of retroviruses share with vectors derived from the
simple onco-retrovirus group the desirable property of
efficient integration into the target cell genome. In addition,
lentivirus vectors appear to have the additional ability to
integrate into a variety of nondividing cells. Not only is this
essential for targeting neural and other terminally differ-
entiated cell types, but is also desirable for targeting the
most primitive HSCs, which are predominantly in a quies-
cent nondividing state. Lentivectors have been engineered
from the lentiviruses of a variety of primate and nonprimate
species. However, considerable effort has been focused on
lentivectors derived from HIV-1, because human cells are
the natural host for this virus and because so much infor-
mation has been derived from the effort to understand the
biology of this major cause of human acquired immune
deficiency. As noted previously, HIV-1 is a complex retro-
virus containing a variety of accessory elements that
enhance the efficiency of such virus life cycle events as
mRNA production, protein production, and intracellular
compartment transport of RNA into or out of the nucleus
(Fig. 3). Unfortunately, many of these accessory elements
are also responsible for some of the pathology associated
with HIV-1. Thus, the critical issue was to design a
lentivirus vector that lacked the pathogenic features of
HIV-1, eliminated the risk of the generation of RCR, but
retained the desirable feature of the ability to integrate
efficiently into nondividing cells.
The recent history of the design of such HIV-1 derived
lentivectors has been achieved in stepwise changes in vector
and packaging elements that some workers in the field have
organized conceptually into different ‘generations’ of
design. While this concept lends itself to delineating design
features and we will use this designation in the following
discussion, it is important to note that there is no consistent
agreement between workers in the field as to what con-
stitutes the 1st, 2nd, 3rd and later generations of vector
design (Fig. 3). All so-called 1st generation designs of
lentivector systems take the successful three-plasmid
approach of the onco-retrovirus vector systems. The transfer
vector is characterized by removal or inactivation of most of
the gag-pol sequence, the env sequence, and all of the
accessory/regulatory genes while retaining the RRE and
TAR sequence, the w packaging recognition region and
the LTRs (Fig. 3E). The 1st generation packaging function
is provided by two plasmids: a gag-pol packaging plasmid
without LTRs or env function, but retaining the regulatory
elements tat and rev, the accessory elements vif, vpr and nef,
but not vpu; and a VSV-G envelope plasmid (Fig. 3B) [118].The 2nd generation changes relate primarily to altera-
tions in the gag-pol packaging plasmid, where additional
accessory genes are removed, and only the two regulatory
elements tat and rev are retained (Fig. 3C) [121]. However,
the absence of vpr reduced transduction of macrophages in
vitro by approximately 50%. Kafri et al. [119] reported good
in vivo transduction of brain, but substantially reduced in
vivo transduction of mouse liver, using HIV-1-based vectors
generated from vpr and vif deleted packaging constructs
when compared to virus particles generated from packaging
constructs bearing all accessory genes. Furthermore, Chin-
nasamy et al. [120] demonstrated that efficient transduction
of resting, but not stimulated, human lymphocytes is
dependent on the presence of accessory genes. Hence,
accessory genes might be required depending on cell type
or activation status.
In the 3rd generation of packaging plasmid design, tat and
rev are both also eliminated from the gag-pol packaging
plasmid, but there is still a requirement for rev, which is
supplied by expression from a separate plasmid to minimize
recombination events (Fig. 3D) [122]. Tat, which binds to
TAR in the transfer vector, acts as a crucial transactivator for
HIV replication. Thus, its deletion abolishes a critical feature
of lentivirus infectivity and enhances biosafety of the vector
system. Transgene expression without tat is restored by
replacing the 5VLTR U3 region of the transfer vector by
constitutively active portions of a heterologous promoter
(such as that from the Rous sarcoma virus [RSV in Fig. 3]).
Additional engineering beyond the 3rd generation system
has been described. It has proved possible to remove the rev
from the packaging system altogether by substituting for the
rev/RRE interaction that facilitates unspliced RNA transport
function. This is achieved by adding a constitutive RNA
transport element (CTE) to the transfer vector, but at the cost
of significant reduction in vector titer [123,124]. CTE
facilitates unspliced RNA export in such onco-retroviruses
as Mason–Pfizer monkey virus. Alternatively, the develop-
ment of synthetic gag/pol expression vectors in which
favored human codon usage replaces wild-type sequence
has allowed deletion of the rev/RRE elements with only
slightly reduced titers [125,126]. Other engineering
approaches to enhance safety and reduce the potential
generation of RCR have focused on separating the gag/pol
function onto two separate plasmids. In such a system, one
of the gag/pol split-packaging constructs generates a pol-
less gag/pro protein, while the other expresses a functional
pol protein (RT and integrase) that is fused to the vpr
domain, which localizes to p6 of gag [127,128]. The gain
of biosafety achieved by this ‘trans-vector’ design is thought
to compensate for a 3- to 5-fold less titer compared to the
typical 3rd generation vector.
Typically, the 3rd generation and later vector designs also
incorporate the SIN feature wherein the transfer vector
plasmid has a deletion created in the U3 region of the 3V
LTR including the TATA box, SP-1 and NF-nB sites (Fig.










































S. Brenner, H.L. Malech / Biochimica et Biophysica Acta 1640 (2003) 1–2414
S. Brenner, H.L. Malech / Biochimica et Biophysica Acta 1640 (2003) 1–24 15copied to the 5Vportion of the provirus cDNA leading to
creation of an inactive 5VLTR. The SIN vector strongly
reduces the potential for RCR and also reduces interference
between the 5VLTR and the required heterologous internal
promoter. Following reverse transcription of such a vector in
the target cell, the nonfunctional 5VLTR that is created from
the U3 deletion-defective 3VLTR abolishes the ability to
produce mRNA. Thus, there is a need to provide a complete
second heterologous promoter in the transfer vector, which
is the only active promoter in the final integrated provirus
insert in the target cells. As will be discussed in more detail
below, a variety of promoters have been used for this
purpose including onco-retrovirus LTR promoters, nonre-
trovirus viral promoters (e.g. cytomegalovirus CMV) or
such human cellular ‘housekeeping’ genes as phosphogly-
cerate kinase (PGK) or elongation factor 1a (EF1a).
Overall, the use of the SIN vector design is associated
with decreased transgene expression levels relative to that
which can be achieved from the virus LTR. A maneuver
taken to enhance transgene expression is the reintroduction
of the central polypurine tract (cPPT) into the transfer
vector. The cPPT apparently promotes nuclear translocation
and increases the amount of integrated vector DNA leading
to higher titer [131,132]. Insertion of the posttranscriptional
regulatory element of the woodchuck hepatitis virus
(WPRE) has also been used to improve transgene expres-
sion by affecting polyadenylation and enhancing nuclear
export of vector RNA. As with onco-retrovirus vectors,
retention of splicing donor and acceptor sites in lentivectors
can promote nuclear export, and together with the presence
of the WPRE, may have additive effects on transport [133].
For some applications, such as genetic correction of the
hemoglobinopathies, there is a requirement for extraordi-
narily high levels of transgene protein production to achieve
clinically useful effects. Recently published work incorpo-
rating selected combinations of proximal and distal genetic
regulatory elements including portions of hemoglobin con-
trol regions into lentivectors have allowed successful cor-
rection of murine models of sickle cell disease or
thalassemia [134–136]. The success of this approach has
made use of another feature of lentivectors relative to the
onco-retrovirus vectors in that the lentivectors can incorpo-
rate much larger amounts of exogenous DNA sequence
without compromising the efficiency of packaging and
production of functional virus vector particles.
When using an SIN type of transfer vector, the efficiency
of transgene expression in the final target cell is highly
dependent on the choice of internal promoter. Furthermore,
the best internal promoter for one target cell type may not be
the best for another cell type. Interestingly, the widely used
CMV promoter, which achieves high transgene expression
in the central nervous system [15], achieves lower expres-
sion in hematopoietic cells, and respiratory syncytia virus
internal promoter does not work at all in hematopoietic
cells. Ramezani et al. [137] studied one of the largest series
of internal promoters in a SIN lentiviral vector including thefollowing promoters: murine stem cell virus (MSCV) LTR,
GALV LTR, EF1 a, CMV and the chimeric promoter CAG,
which consists of the chicken h-actin promoter and the
CMV immediate early enhancer. Highest transgene levels in
an hematopoietic progenitor cell line were found for the
MSCV LTR as internal promoter and lowest for the CMVas
internal promoter. Though WPRE insertion was found to
enhance transgene expression, the effect was variable
depending on the target cell and promoter. Recent studies
using transfer vectors containing the EF1 a promoter
suggest that this is a particularly good choice for achieving
high transgene expression in hematopoietic cells [138].
Transgene expression from the human PGK promoter
resulted in transgene levels in hematopoietic progenitors
intermediate between CMV and EF1 a, and may be another
good choice for studies of hematopoietic cells. In this study,
insertion of the WPRE element upstream of the 3V LTR
helped to increase transgene expression in SIN vectors using
human CD34+ HSCs.
It is clear from the discussion above that intensive
engineering has been required to generate 3rd and later
generation HIV-1-based lentivectors containing the safety
features that might allow them to be brought to the clinic.
As previously noted, the reason for such intensive investiga-
tional activity in this area is the promise that such lentivec-
tors might retain the critical biological feature of wild-type
lentivirus; an ability to stably integrate into both nondivid-
ing terminally differentiated cells and quiescent stem cells,
which are resistant to onco-retrovirus transduction. Lenti-
vectors at different generations of development have been
tested for their ability to transduce such cells. Using 1st and
2nd generation lentivector systems, stable transgene expres-
sion after in vivo transduction was shown for rat brain [118],
liver and muscle [119], retinal cells [139 ] and airway
epithelial cells [140]. Ex vivo transduction, followed by
transplantation and long-term transgene expression, was
seen in murine pancreatic islet cells [141]. Transduction of
quiescent human HSCs was first shown in vitro using cord
blood, bone marrow or mobilized peripheral blood as stem
cell source [142,143]. Transduction of nonhuman primate
HSCs with a 1st generation lentivirus vector demonstrated
1–10% marking of multilineage peripheral blood cells in
vivo [144,145]. In vivo evaluation of ex vivo transduced
human HSCs is enabled by transplanting such cells into
irradiated NOD/SCID mice to achieve human–mouse bone
marrow chimeras. Miyoshi et al. [146] were able to effi-
ciently transduce human cord blood CD34+ cells with 2nd
generation HIV-1 derived lentivector expressing green fluo-
rescent protein without the need to add exogenous growth
factors to the culture. These are conditions where there is
minimal cell division by the CD34+ cells and little trans-
duction by onco-retrovirus vector. When these lentivector-
transduced human cord blood CD34+ cells were adminis-
tered to irradiated NOD/SCID mice, up to 27% of long-term
engrafted human cells in the chimeric mice bone marrow
expressed the green fluorescent protein.
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terminally differentiated neurons of nonhuman primates
and [147] and efficient gene transfer into NOD/SCID
repopulating mobilized peripheral blood human CD34+
HSCs has been demonstrated [19]. Of note is that in all of
the in vivo animal studies mentioned above, no pathology
was observed that could specifically be attributed to lenti-
vectors. While studies in mice (including assessment of
human stem cells in the NOD/SCID mouse–human chimera
model) are convenient to assess the initial aspects of new
vectors, it should be noted that it also is important to assess
safety and efficacy issues of gene therapy in large animal
models that may present barriers to effective gene therapy
more similar to those that will be encountered with human
patients in the clinic. Moreover, mice may not live long
enough to assess long-term efficacy or to observe the
emergence of toxicities that require a long latency. Finally,
while the NOD/SCID mouse–human marrow chimera
model is an important surrogate for assessing the repopulat-
ing potential of human stem cells, it has not be established
that there is identity between those stem cells responsible for
permanent repopulation of human subjects and those cells
which engraft in the NOD/SCID mouse.
Lentivectors have also been developed from HIV-2. The
HIV-2-based vector, designed by Poeschla et al. [148], used
a gag-pol packaging plasmid that carried deletions in both w
and env, with the accessory genes remaining, and a polyA
signal fused to the nef stop codon. As with the HIV-1
systems, a VSV-G plasmid supplied the deleted env func-
tion. HIV-2 transfer vector also has been used in hybrid
systems with the HIV-1-derived packaging elements as an
alternative approach to reduce the risk of recombination
events between overlapping sequences in the transfer plas-
mid and the gag-pol packaging plasmid. This HIV-2 transfer
vector produced from a stable HIV-1 packaging cell line
(w422) was able to transduce human macrophages [149].
The history of SIV lentivector development is analogous
to the 1st, 2nd and 3rd generation of HIV-1 vectors.
Properly pseudotyped SIV-based vectors can transduce non-
dividing human cells, such as neurons and macrophages but
no expression was found in CD34+ CD38 nondividing
cells, and transduction efficiency was not compared to the
efficiency of similar HIV-1-based vectors [150,151]. As
with HIV-2 transfer vectors, hybrid HIV-1/SIV vector sys-
tems have been developed and provide some safety advan-
tages since the nucleotide homology between both viruses is
low. With this approach HIV-1-based transfer vectors could
be packaged by SIV core particles and visa versa and both
types of vector hybrids were able to transduce human
nondividing cells [150,152].
Nonprimate lentivirus vectors have also been developed.
In contrast to primate lentiviruses, these viruses have a
dUTPase to minimize mutations from dUTP misincorpora-
tion during reverse transcription. Theoretically, this might
lead to higher fidelity of sequence replication. Compared to
HIV, little is known about nonprimate lentiviruses, but it ispossible that there is a safety factor to be derived from use
of such vectors. Although FIV has the potential to infect
human cells in vitro, no transmission of the virus to humans
through the bite of infected cats has been reported [153]. In
an attempt to develop FIV-based vectors, Poeschla et al.
[154] had to overcome the low transcriptional activity from
the 5V LTR in human cells by replacing the viral U3 region
with the CMV promoter. Johnston et al. [155] further
demonstrated that in analogy to the HIV-based vectors, the
accessory genes vif and orf2 of FIV were not necessary for
transduction of either dividing or nondividing cells in vitro.
As with the HIV-1 system, Curran et al. [156] were able to
replace the rev/RRE system with the functionally related
CTE from the Mason–Pfizer monkey retrovirus. It was not
possible to create hybrid systems using packaging plasmids
from FIV or HIV-1 with transfer plasmids from HIV-1 or
FIV, respectively. A three-plasmid EIAV vector system has
been shown to efficiently transduce aphidicolin arrested
CFT1 airway epithelial cells in vitro and neuronal rat cells
in vivo, respectively [157,158]. Berkowitz et al. [159]
developed a BIV-based vector, which efficiently transduced
a variety of human and nonhuman dividing and nondividing
cells. When targeting nondividing human mobilized periph-
eral blood CD34+ HSCs, this vector was less efficient than
an HIV-1 derived vector. A gene transfer system using the
sheep lentivirus, Visna, also appeared to be less efficient in
targeting human cells [160].
Retrovirus vector gene transfer is limited at the level of
virus entry by envelope pseudotyping (see Section 3.1.5),
but reverse transcription, nuclear transport and integration is
also limited by intracellular factors, which affect these post-
entry events. One example of such factors are the saturable
restriction factors determined by the mouse gene Fv1 and
the human Ref1, which appear to selectively block infection
by certain MLV strains. Another example is the recently
described Lv1 factor that restricts in a dominant fashion the
HIV-1 replication and likely HIV-1 lentivector integration in
nonhuman primates. This and possibly other post-entry
restrictions probably explain the low gene transfer efficiency
reported for HIV-1-based lentivirus vectors in nonhuman
primate models [161–165].
At this time, the HIV-1-based lentivectors appear to be
the best developed, the safest and the most efficient of the
lentivirus group for application to human HSCs. They retain
their advantage over onco-retrovirus vectors by their ability
to target nondividing cells and by their larger packaging
capacity. However, the later generations of this system may
not be as efficient in their capacity to target some non-
dividing cells such as the quiescent HSC than the earlier
generations of this system. The later generation systems
may also have lower production of transgene protein than
can be achieved with onco-retroviruses, though the newer
lentivectors of this series containing additional control
elements and/or better promoters may overcome this latter
problem (e.g. the new constructs noted above for correction
of the hemoglobinopathies).
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In Section 2 above, it was noted that foamy virus is of
interest because it is a complex retrovirus with accessory
elements that may enhance its ability to transduce non-
dividing cells. Furthermore, foamy virus envelope itself
confers broad tropism so that it may be used as part of this
vector system rather than pseudotyping with other types of
envelopes. Current foamy-virus-derived vectors consist of
two constructs, the transfer vector and the packaging plas-
mid. In contrast to initial data, which suggested cell cycle
dependence for foamy virus integration [166] and expres-
sion of virus encoded genes [167], Mergia et al. [168]
demonstrated in concordance with others [169,170] efficient
transduction of nondividing cells in culture with foamy
virus vectors. Specifically, G1/S (aphidicolin) arrested cell
lines and unstimulated human lymphocytes were efficiently
transduced with a simian-foamy-virus-derived vector, but
not with an MLV-based vector. The authors point out that a
reason for the contradictory results upon cell cycle depend-
ence could be that parental foamy virus LTR-driven gene
expression is low or undetectable compared to expression
driven by an internal promoter, such as CMV, which was
used by this and other groups. Progress has been made in
terms of biosafety by development of foamy virus vector
without the transcriptional trans-activator bel1. This step
was accomplished by introduction of alternate promoters
such as a strong 5V CMV-LTR fusion promoter or the
promoter from MSCV [171,172]. Using the latter vector
together with the CH-296 human fibronectin fragment, very
high rates of transduction of human cord blood CD34+ stem
cells or murine bone marrow stem cells could be achieved.
Though this group used vector made with foamy virus
envelope, others have had difficulty achieving high rates
of transduction of human CD34+ cells unless foamy virus
vectors were pseudotyped with other envelopes. In a recent
study, foamy virus vector expressing GFP achieved high
transduction efficiency in human cord blood CD34+ NOD/
SCID repopulating cells [173]. Further development of the
foamy virus group of vectors remains a promising direction;
however, work is needed to delineate the minimum virus
elements needed to achieve efficient transduction in order to
reduce the risk of RCR.
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4.1. Materials and methods for transduction enhancement
Transduction efficiency is greatly related to vector trop-
ism; however, several other factors remarkably enhance
transduction. For transduction with onco-retrovirus, cells
have to go through one cell division cycle for successful
integration as mentioned previously [174]. For successful
transduction of HSCs with lentiviral vectors, cells have to be
at least in cell cycle phase G1b, but transduction efficiency
clearly benefits from the intracellular biological changesassociated with entry into active cell cycling. Ex vivo
stimulation of HSCs with growth factors is thus required
for transduction with onco-retrovirus vectors and highly
conducive to lentivector transduction. Furthermore, cyto-
kine growth factors maintain cell viability during the ex
vivo manipulations and may also affect such factors as the
intracellular supply of deoxynucleotide-triphosphates. How-
ever, prolonged culture of HSCs results in cell differentia-
tion and loss of reconstitution potential. Much effort has
been expended on determining optimum growth factor
combinations and other culture conditions to enhance trans-
duction while maintaining reconstitution potential. The
ultimate goal of being able to expand HSCs ex vivo for
any prolonged period while preserving long term repopulat-
ing potential has not been achieved.
Marrow stromal cells in vivo play a very important role
of providing both an optimum adhesive matrix and optimum
presentation of critical cytokines to HSCs. Establishing this
matrix ex vivo by co-culture of HSCs with autologous
marrow stromal cells appears to promote gene transfer. This
approach has been tried in the clinic but there are significant
technical difficulties to the clinical scale up for this
approach, involving the culture of many flasks of autolo-
gous stroma. It has been suggested that noncellular matrix
elements might serve to replace the effect of stromal cells ex
vivo. Of all of the stromal matrix elements studied, how-
ever, it appears that coating the surface of the tissue culture
vessel with a particular fragment of human fibronectin that
includes the heparin-binding site, the CS-1 region and the
VLA-4 and VLA-5 binding sites greatly enhances trans-
duction using retrovirus vectors. Curiously, the transduc-
tion-enhancing properties of this fragment of fibronectin are
not reproduced by using the intact fibronectin molecule. A
recombinant version of a fragment from the active region
(CH-296) is commercially available as Retronectink
(Takara Biomedical, Otsu, Japan) and has been used in a
number of clinical trials. The enhancement effect achieved
by coating the vessel surface with Retronectink has been
attributed simply to co-localization at the vessel surface of
the virus vector attaching to the heparin-binding region of
the fibronectin fragment and the cells as they attach to the
VLA-4 and/or VLA-5 binding sites [175–177]. However, it
is possible that in the case of HSC, the CS-1 domain also
exerts other biological effects on HSC, which bind to this
fibronectin fragment, such as preservation of repopulating
potential. There is some controversy about which vector
envelopes are associated with Retronectink-mediated
enhancement of transduction. For example, it is not firmly
established whether the VSV-G pseudotype is associated
with such enhancement or in particular whether transduction
with VSV-G pseudotyped lentivectors is enhanced by Ret-
ronectink. Our own experience suggests that there is a
Retronectink-mediated enhancement of transduction by
VSV-G pseudotyped lentivector [19,20].
Two other maneuvers have been shown to enhance trans-
duction with retrovirus vectors. Polycationic molecules have
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infections in culture. This is thought to be primarily an
electrostatic effect that brings virus to the cell surface, but
other effects on cell membranes cannot be ruled out. Because
protamine sulfate is a cationic molecule, which has been
used clinically to reverse the effects of overtreatment with
heparin, it has been the cationic agent of choice to enhance
retrovirus vector transduction ex vivo in the clinical treat-
ment setting. The other maneuver that appears to augment
transduction by retrovirus vectors has been ‘‘spinoculation’’,
which is a neologism coined to describe low-speed centri-
fugation (up to 1200 g) used at the start of transduction to
mediate enhancement of gene transfer. Its effect is thought to
be achieved by enhanced vector/cell interaction. Our own
experience has been that for most onco-retrovirus and
lentivirus vectors and cell targets (including human HSC),
combining RetronectinR coating of the culture vessel, addi-
tion of protamine to the medium, and spinoculation results in
higher transduction than use of any of these maneuvers alone
or in combination of two. In this regard and in contrast to our
own experience, other investigators report that use of pro-
tamine with RetronectinR decreases the transduction
enhancement seen with RetronectinR alone [178]. Ex vivo
co-culture of HSCs with vector producing cells also has been
shown to increase transduction efficiency, but for safety
reasons, co-cultivation of HSC with producer lines has been
avoided for clinical applications.
As noted in the sections above, the density of envelope
receptors on human HSC is very important to determining
the efficiency of transduction of HSC by vectors sharing a
particular envelope pseudotype. However, for different lots
of vector with the same envelope pseudotype, both the
infective titer of retrovirus and the multiplicity of infection
(MOI) appear to affect the rates of transduction. In general,
if the MOI is over 5 (i.e. there are more than five infectious
virus particles for each cell target), the concentration of
infective virus (i.e. titer) plays a much greater role in
determining the final transduction efficiency. The efficiency
of transduction from a low titer vector cannot be improved
simply by decreasing the concentration of cells (increasing
the MOI) if the MOI is already well over 5 [13,138].
The stability of virus particles is greatly influenced by
freeze and thaw cycles, pH and temperature. According to
Higashikawa and Chang [179], the half-lives of HIV-1 and
MLV vectors at 37 jC, determined by vector titer, were 10.4
and 4.5 h, respectively. A pH other than 7.0 resulted in
remarkable loss of vector stability. Interestingly, in that
study, more than 99% of VSV-G-pseudotyped virus par-
ticles were defective. The defective particles, however,
could largely be eliminated by a centrifugation step that
concentrated primarily the infective virus.
4.2. Biosafety issues
Insertional oncogenesis is a biosafety issue common to
the use of all integrating vectors in all gene therapy settings.This was discussed in considerable detail in Section 3.1.1.
Related to that concern is the potential of RCR production,
which may cause disease directly from the virus replication,
but may also cause cancers from the very high rates of
insertional mutagenesis. There is also concern that RCR
could insert into gonadal tissues (also a concern from direct
in vivo administration of replication incompetent retrovirus
vectors). Certain maneuvers might diminish the risk of
insertional mutagenesis. The use of low MOIs for trans-
duction of stem cells reduces the number of vector inte-
grants per cell and thus could reduce the risk of insertional
mutagenesis. SIN vectors with (transgene specific) tissue-
regulated internal promoters instead of virus LTR-driven
vectors might reduce the risk of activating neighboring
genes. Influence of vector enhancer elements on neighbor-
ing sequences also might be diminished by inclusion of
chromatin insulators. One goal is the design of vehicles and
methods that result specifically in integration into sequences
that are thought to be safe and do not trigger unwanted side
effects. Ultimately, efficient methods of gene therapy that
repair an affected gene in situ would be best, but at present
is only a theoretical future goal.
A complete review of all of the potential safety issues
related to gene therapy targeting HSCs is beyond the scope of
this review. For a detailed review of biosafety issues associ-
ated with HSC retroviral gene therapy, the authors would like
to recommend the recent publication by Baum et al. [180].
4.2.1. Vector production
There are a number of safety and scale-up considerations
relating to production of retrovirus vectors for clinical use.
Production of vector can either rely on use of a stable
producer line or a transient production system. Each
approach has its advantages and disadvantages with respect
to practical and safety issues. Vector production for most
clinical trials using onco-retrovirus vectors have relied on a
stable producer cell line as the source of replication-incom-
petent infectious vector particles. In general a stable onco-
retrovirus producer line is a cloned and highly characterized
line demonstrating both stable phenotypic features (such as
growth rate, adherence behavior, virus production titer) and
stable genomic elements. This approach has the advantage
of stability and reliability in that it is possible to develop
standard conditions for scale up of the producer line that are
likely to lead to predictable outcomes. In addition, it is
possible to establish master cell banks and working cell
banks (frozen vials of the producer cells from a single
culture lot) that have undergone all of the specialized safety
testing required by the US FDA. Such testing includes, but
may not be limited to, establishment of the identity of the
line, demonstration of the sequence integrity of the vector
genomic elements, absence of adventitious infectious
agents, and absence of RCRs. The final vector must go
through the same testing as indicated for the cell banks
including the demonstration that the complete vector
sequence in the lot to be used clinically matches the
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adequate for the clinical trial. Most of the first generation
of genetically engineered producer lines are derived from a
murine NIH 3T3 parent line, but a number of improved
producer lines have been constructed in the last few years
from cell lines of other species including those based on the
human 293 mesenchymal embryonic kidney cell line or the
human HT1080 sarcoma cell line (Table 1).
The alternative approach to vector production is to use a
highly characterized cell line, such as the human 293T cell
line, that contains no vector system genetic elements, but is
highly receptive to transfection with exogenous DNA and
supports high levels of transient expression from DNA
constructs taken up by the transient producer cell line.
Hybrid approaches have also been devised in which a
293T cell is engineered to contain packaging elements
permanently integrated, where it is only necessary to trans-
fect transfer vector plasmid for transient expression. One
advantage of transient expression systems to produce retro-
virus vector is that the same highly characterized and safety-
tested transient producer line can be used to package many
different types of transfer vectors or with different envelope
pseudotypes. The other advantage is that the transient
expression systems allow production of vector system
elements with toxicities that preclude establishment of a
permanent cell line expressing these elements. For example,
the VSV-G envelope exhibits toxicities, which prevent
permanent expression by a stable producer line. Thus,
production of VSV-G-pseudotyped retrovirus vectors is best
achieved using a transient expression system, though a
number of laboratories have been working toward develop-
ing conditional systems with regulated promoter elements
that may allow establishment of stable VSV-G pseudotyping
producer cell lines that produce high-titer retrovirus vector
only under conditions permissive to the regulated promoter
expression.
As will be noted below, when discussing the clinical
scale up of culture and transduction, safety considerations
have led to the development of approaches to vector
production and preparation, which eliminate immunogenic
exogenous materials such as fetal bovine serum. One
approach that has been used for production of clinical grade
onco-retrovirus vector has been to switch the producer line
to serum-free medium during the collection of vector super-
natant [181]. Our experience is that most of the commonly
used producer lines, particularly the 293 cell or HT1080-
cell-based producer lines will tolerate short-term replace-
ment (up to 12 h) of their regular growth medium with any
of the specialized serum-free media (such as X-VIVO 10k)
developed for growth of human HSC without loss of
infectious virus titer as long as the producer cell line is
allowed to recover for a period in its regular growth medium
before switching medium for a second vector supernatant
collection in the serum-free medium. It may also be possible
to perform this maneuver in the setting of transient expres-
sion vector production.VSV-G and RD114 pseudotyped vectors can be concen-
trated by sedimentation using high-speed centrifugation
without loss of infective titer [90,92,95,96]. Other
approaches to vector purification include the use of ion
exchange, sizing gel columns or other separation technolo-
gies that can serve to purify infectious retrovirus vector and
eliminate the inhibitory, toxic or antigenic substances
present in the spend culture supernatant into which the
vector particles are shed by the producer cell line [21]. It
is likely that use of maneuvers which purify retrovirus
vector will be the preferred method of vector preparation
for clinical application of retrovirus-based gene therapy
because it will allow greater standardization of vector
particle preparations, will increase the safety of the vector
particles, and will likely enhance vector performance.
4.2.2. Clinical scale-up of culture and transduction
For a variety of reasons it has not been practical to
consider administering onco-retrovirus vectors to patients in
vivo for gene therapy of hematopoietic disorders. This is
because the hematopoietic organ (the bone marrow) is
dispersed in many bones throughout the body, making
intramarrow injection of vector impractical; inactivation of
virus by the human complement system makes intravenous
or intramarrow administration relatively ineffective; and
safety considerations dictate the use of methods that restrict
transduction of therapeutic genes into only the target tissues.
These reasons have led to the development of safe methods
for transducing CD34+ HSC ex vivo. This approach has the
advantage of limiting transduction to the target tissue of
interest and eliminating exposure of the patient to infectious
vector. As noted above in the discussion of retrovirus vector
production, safety considerations have driven the commer-
cial development of culture media that will support the
growth of HSC without a requirement for fetal bovine serum
or other animal sera, though most of the serum-free media
available to culture human HSC do require a protein supple-
ment such as 1% human serum albumin [182]. One example
of such a medium used in clinical trials is the X-VIVO 10k
medium (BioWhittaker) supplemented with 1% human
serum albumin. Hopefully, in the future, even the human
serum albumin (which must be purified from human blood)
may be replaced by a recombinant protein source. As noted
in other discussions above, optimum transduction requires
also the addition of recombinant cytokine growth factors to
this medium.
For nonclinical laboratory research-scale culture and
transduction of CD34+ HSC, the widely used standard tissue
culture materials and techniques are practical, convenient
and adequate. For clinical application and scale-up, the use
of these research laboratory methods is time-consuming and
the risk of contamination probably increases proportionately
to the number of flasks or plates used and the number of
hand pipette manipulations or other individual maneuvers
required. It would be helpful to have a culture and trans-
duction system, which integrates easily into standard blood
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banks uses a patented automated process employing a
disposable hot blade that can sterilely connect the plastic
tubes on blood bags even when there is liquid in the tubes
that are to be connected. Flexible plastic bags have been
developed (X-FOLDk bags produced by Baxter Health-
care), which are highly gas permeable. Large surface area/
volume bags are available and in addition many bags can be
connected together through their plastic tubing connections
to greatly simplify the culturing and handling issues asso-
ciated with clinical scale up. Furthermore, the inner surface
of the bags has the electrostatic charge properties that allow
coating of the bags with Retronectink exactly as can be
done with regular tissue culture ware, and with the same
enhancement of retrovirus mediated transduction. This type
of flexible gas permeable plastic bag culture system has
been used in several clinical trials since its first application
in a clinical trial reported in 1997, including the recent trials
demonstrating clinically beneficial gene therapy treatment
of X-SCID, and is likely to become the standard for ex vivo
HSC gene therapy [1,2,181,183].5. Clinical experience with onco-retrovirus vectors and
prospects for clinical application of lentivector
It is beyond the scope of this review to summarize in detail
onco-retrovirus vector clinical gene transfer trials [184,185].
There is general information on human gene therapy proto-
cols in the USA available at http://www4.od.nih.gov/oba/.
There is extensive clinical experience with the use of onco-
retrovirus vectors for ex vivo gene marking or gene therapy
targeting HSCs and T lymphocytes. Such studies can be
roughly divided into the following types of studies: gene
marking studies performed to follow the in vivo fate of HSC
or lymphocytes marked ex vivo; transduction of genes that
protect HSC or lymphocytes, respectively, against intensive
chemotherapy or against infection by HIV; transduction of a
‘‘suicide gene’’ such as herpes virus thymidine kinase into T
lymphocytes to allow removal with ganciclovir after the T
cells have accomplished some therapeutic goal such as anti-
tumor activity, protection against viral infection, or enhance-
ment of allogeneic engraftment; and transduction of thera-
peutic genes into HSC or T lymphocytes to treat metabolic
disorders such as Gaucher’s disease or immune deficiencies
such as SCID, leukocyte adhesion deficiency or chronic
granulomatous disease. While valuable information has been
obtained from many of these clinical trials, the majority of
these clinical trials have resulted in only very low levels of
marking of stem cells [181,186–188] and moderate levels of
marking of lymphocytes [42,189]. Furthermore, except for
trials in infants and young children, marking has been
prolonged (a year or more), but not permanent. The first
exceptions to this general experience are the recent reports of
unequivocal clinical benefit provided in trials of gene therapy
for patients with X-SCID and ADA-SCID [1,2]. In the lattertrial, as mentioned before, marrow conditioning supported
engraftment of the gene corrected HSC and appeared to
enhance the selective growth. This highlights the fact that
for successful gene therapy for diseases other than X-SCID,
chemotherapy or radiation conditioning is required to sup-
press resident bone marrow cells and establish a suitable
environment for the incoming ex vivo transduced cells even
where there is a selective growth advantage provided by the
therapeutic gene product. It may be that other maneuvers
could also enhance engraftment. For example, in a murine
transplant model, engraftment could be improved by G-CSF
administration prior to transplantation [190]. Though the best
engraftment of gene marked HSC can be achieved in nonhu-
man primates using myoablative conditioning, risk–benefit
considerations preclude conditioning regimens, which result
in complete bone marrow ablation for treatment of noncancer
disorders such as inherited metabolic or immune deficiencies
[40,41,191,192]. Thus, achievement of clinical benefit with
gene therapy targeting HSC for inherited hematopoietic
disorders in which no selective advantage accrues from
replacing the defective gene product with a transgene encod-
ing the normal therapeutic gene product will likely require
both non-ablative marrow conditioning and the co-expres-
sion of a gene providing a conditional selective growth or
survival advantage. These issues and the current technology
developed to address this problem have been discussed in
greater detail in the sections above.
No clinical gene therapy trials have been conducted
using lentivirus- or spumavirus-derived vectors. Particularly
with the HIV-1-derived 3rd and later generations of SIN
lentivectors, safety features engineered into these vectors
that minimize the risk of recombination have made it likely
that these current generations of highly modified lentivec-
tors are being considered to be acceptable for clinical
application. Lenti- and spumavirus-derived vectors can
infect terminally differentiated and quiescent cells and will
therefore be particularly advantageous for transducing tis-
sues that do not divide (e.g. neurons for treatment of
neurodegenerative diseases) or that are relatively difficult
to induce to divide (e.g. HSC for treatment of hematopoietic
disorders). Furthermore, lentivector or spumavirus provirus
present in engrafted transduced HSC may be less subject to
silencing over the long term in vivo than murine onco-
retrovirus vectors. These features could make these or
related vectors the constructs of choice in the future. Safety
considerations make it likely that there will be a bias of the
regulatory agencies toward initial clinical studies with
lentivector that use an ex vivo approach to treatment in
order to avoid direct administration of lentivector to the
patient in vivo. Because of the ease of harvesting and
culturing HSC ex vivo, this increases the likelihood that
the first clinical trial with lentivector may be conducted with
HSC as the target tissue.
All of the safety issues relating to onco-retrovirus vectors
apply to HIV-1-based lentivirus vectors. In addition, there
are issues unique to the lentivector. First, in its wild-type
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There is emphasized concern with minimizing the potential
to recreate even small portions of active regions of this
virus. Removal of all accessory genes, using split packaging
constructs, codon switching to further reduce potential of
recombination, and the use of SIN feature to exclude active
LTR from the insert are all maneuvers designed to achieve a
level of safety to gain regulatory approval. Concerns remain
that even the portions of the HIV-1 gene left in place could
have pathological consequences that would only be seen in
human trials or that could be exacerbated in patients carry-
ing wild-type HIV-1 (even without recombinational events).
There is even debate about whether the first lentivector
studies should avoid trials with HIV-1-infected patients to
reduce potential for recombination, or on the other hand,
should target HIV-1-infected patients first since they already
have an infection. One factor limiting initiation of lentivec-
tor clinical trials is the need to achieve good clinical scale
production methods (since only transfection mediated tran-
sient virus production methods are capable currently of
reaching the titers necessary to conduct a clinical trial).
Regulatory agencies need to finalize recommendations for
specific safety testing for these agents [193].
As of this writing, February 2003, all clinical gene therapy
trials with retrovirus vectors are currently halted due to the
serious adverse event in two gene-therapy treated X-SCID
patients from the French trial. It will be extremely important
to elucidate the pathophysiology that led to generation of the
leukemia in these patients. This problem likely will spur
investigation more generally of patterns of insertion sites
including proximity to and effects on a variety of oncogenes
and other targets. We do not know if these adverse events are
unique to the X-SCID gene therapy setting, or if this is a
harbinger of problems that could arise in tandem with
achievement of high levels of permanent gene correction
with integrating vectors in other clinical settings.Acknowledgements
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